Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis - 07/09/11
Abstract |
Background: Doxepin applied topically by itself or in combination with triamcinolone acetonide is a safe and effective treatment for atopic dermatitis. Objective: We evaluated the pharmacokinetic profile of doxepin and desmethyldoxepin after topical application of doxepin hydrochloride 5% cream alone or in combination with 0.025% triamcinolone acetonide (doxepin/TAC). Methods: Twenty-four subjects with atopic dermatitis received either doxepin or doxepin/TAC cream 4 times daily for 7 days in a randomized, double-blind, controlled trial. Serum samples were obtained and pharmacokinetic parameters estimated from the dose-normalized serum concentrations of doxepin and desmethyldoxepin. Efficacy and adverse experiences were determined by physician and subject evaluations. Results: Pharmacokinetic parameters (Ke , t1/2 and AUC) calculated in 9 subjects (doxepin/TAC = 4 subjects, doxepin = 5 subjects) with detectable serum concentrations were similar for both groups. Pruritus relief and lessening of pruritus severity were significantly greater with doxepin/TAC than doxepin alone. Conclusion: Topically applied doxepin is safe and effective therapy for pruritus. (J Am Acad Dermatol 1999;41:209-14.)
Le texte complet de cet article est disponible en PDF.Plan
From the Dermatology Clinical Investigations Unit,a the Pediatric Psychopharmacology Unit, Department of Psychiatry and Department of Pharmacy,b and the Department of Chemistry,c Massachusetts General Hospital. |
|
Supported in part by GenDerm Corporation, Lincolnshire, Ill. |
|
Reprint requests: Lynn A. Drake, MD, Dermatology-BAR 604, Massachusetts General Hospital, 40 Blossom St, Boston, MA 02114-2696. |
|
0190-9622/99/$8.00 + 0 16/1/98491 |
Vol 41 - N° 2
P. 209-214 - août 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?